Skip to main content
. 2014 Mar 21;5(9):2551–2561. doi: 10.18632/oncotarget.1838

Figure 3. Kaplan-Meier estimates of survival for astrocytic tumor patients.

Figure 3

a. Among patients with astrocytic tumors of all grades, there was no significant difference in survival between anaplastic astrocytomas and GBMs when patients were only stratified by the histopathological diagnosis of their tumors. b, c, d. ATRX, IDH1/2 status and Ki-67 are biomarkers associated with survival of patients in astrocytic tumors. e. Among all patients with astrocytic tumors (n=139, except non-classifiable), there was a significant difference in overall survival between the new three subgroups, and the A1 group and A2 group survived significantly longer (median OS, 1208 and 689 days, respectively) than the A3 group (309 days; P<0.0001).